Clinical Trials in Chubbuck, Idaho
6 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 2
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Glomerulonephritis, IGAImmunoglobulin A Nephropathy
Novartis Pharmaceuticals20 enrolled18 locationsNCT06797518
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
CKDMetabolic Acidosis
Renibus Therapeutics, Inc.150 enrolled16 locationsNCT07355062
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled202 locationsNCT05797610
Recruiting
Phase 2
BAY3401016; Biomarker Study Alport
Alport Syndrome
Bayer60 enrolled60 locationsNCT07211685
Recruiting
Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Prokidney685 enrolled95 locationsNCT05099770